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1. Introduction
  Epidermal growth factor receptor (EGFR) belongs to 
receptor tyrosine kinase (RTK) and is the expression 
product of pro-oncogene ErbB1 (HER1). EGFR participates 
in the information control process in many cells, and its 
abnormal expression is closely related to many malignant 
tumors. After binding its ligand, EGFR gave priority to form 
heterodimer with HER2. After receptor dimerization, the 
EGFR dimer activates the PTK, and phosphorylation also 
occurs in its tyrosine residue. Subsequently, EGFR activates 
ERK/MAPK, phosphatidyl-inositol-3-kinase (PI3K), JAK/
STAT pathway and the downstream effectors to regulate cell 
proliferation, migration, survival and tumor angiogenesis[1,2]. 
EGFR highly expresses in many malignant tumors and 
is related to the growth and invasion of tumors[3]. Lots 
of reports about EGFR can be seen in the gastric cancer 
associated literatures[4-6]. Recent studies about gastric 
cancer have indicated that EGFR highly expresses in 
gastric cancer and is closely related to the occurrence, 
development and biological behaviour of gastric cancer, 
and it is regarded as the ideal target in the treatment of 
tumors like gastric cancer. The biotherapy regarding EGFR 
as the target becomes the new research hotspot of gastric 
cancer[7-10]. This study adopted the immunohistochemical 
method to detect and analyze the EGFR expression in 
gastric adenocarcinoma tissues and adjacent normal gastric 
mucosa tissues in order to explore the clinical significance 
of using EGFR as the molecular target to guide the targeted 
therapy for gastric cancer.    
Objective: To investigate the relationship between the expression of epidermal growth 
factor receptor (EGFR) in gastric cancer and the clinicopathological features and prognosis. 
Methods: A total of 78 paraffin specimens of gastric cancer operation were collected. The 
immunohistochemical method was used to detect the expression of EGFR in 78 cases of gastric 
cancer and 20 cases of adjacent normal tissue. The relationship between the high expression of 
EGFR and clinicopathological features was analyzed. Results: EGFR positive expression rate in 
the 78 cases of gastric cancer tissue was 57.7 %( 45/78), while EGFR was not expressed in 20 cases 
of adjacent normal tissue. The high EGFR expression was positively correlated with the position 
of gastric cancer, tumor size, cell differentiation, invasive depth, lymph node metastasis and TNM 
staging, yet having no obvious relation with gender or age. Conclusions: EGFR expression level 
in gastric cancer is closely related to the incidence and development of gastric cancer, which can 
provide a theoretical basis for the targeted therapy for gastric cancer with EGFR as the target.
Ming Gao et al./Asian Pacific Journal of Tropical Medicine (2013)260-264 261
2. Materials and methods
2.1. Specimens
  The paraffin specimens of 78 cases of gastric cancer 
tissue and 20 cases of adjacent normal gastric tissue were 
provided by Pathology Department, First Affiliated Hospital 
of Zhengzhou University which collected them during March 
2000 and March 2007. Clinical stage was made according to 
the TNM staging criteria formulated by International Union 
against Cancer and American Joint Committee on Cancer.    
2.2. Reagents and instruments
  EGFR mouse anti-human monoclonal antibody (Product 
No. MAB-0196). The ready-to-use MaxVision detection kit 
and dimethylaminoazobenzene chromogenic reagent were 
purchased from Fuzhou Maixin Biotechnology Development 
Company. 
  Instruments: paraffin slicing machine, microscope, and 
electrothermal constant-temperature dry box. The images 
under microscope were captured and analyzed by Olympus 
Dp70 image analyzer.  
2.3. Experimental method
  The paraffin specimens were made into 3-5 毺m sections. 
The sections were put into the 65 曟 electrothermal constant-
temperature dry box overnight and then deparaffinized. 
EGFR underwent enzymatic digestion and antigen retrieval 
by gastric enzyme. Then the product was incubated for 30 
min in 37 曟 water bath. It was washed by PBS solution for 3 
min, and soaked by H2O2 100 mL+CH3OH 900 mL solution for 
10 min. After washed 3 times by PBS, the first antibody was 
added, overnight in the refrigerator at 4 曟. After washed 
twice by PBS, the ready-to-use MaxVision detection kit 
was added at room temperature. 4 0min was given for full 
reaction. After washed three times by PBS, DAB coloration 
was conducted. It was counterstained by hematoxylin, 
and than wasdehydrated, mounted and observed under 
microscope.  
2.4. Judgement of results
  The positive and negative controls were set for all the 
experiments. Brownish yellow granular precipitation in 
the cell membrane and cytoplasm indicated the positive 
expression of EGFR, while there was no brownish yellow 
granular precipitation in the negative cells. 
  Staining grade: No positive cells in the whole section (-), 
the number of positive cells<10 %(+), the number of positive 
cells 10%-50 %(++), the number of positive cells 曒50 %(+++). 
2.5. Statistical analysis
  SPSS17.0 software was utilized to perform statistical 
analysis. A P<0.05 was taken to indicate a difference of 
statistical significance. 
3. Results
3.1. EGFR expression in gastric cancer
  The expression rate of EGFR in gastric cancer was 53.7% 
(45/78), but it did not express in normal gastric tissue. EGFR 
only expressed in cell membrane or cytoplasm without 
nucleus staining (Figure 1). EGFR protein expression had no 
significant correlation with patients’ gender and age, but it 
was correlated to tumor position, tumor size, differentiation, 
invasive depth, lymph node metastasis, distant metastasis 
and clinical stage. The EGFR positive expression rates of 
patients with tumor diameter 曒5 cm, tumor located in the 
middle part, poor differentiation, infiltration into serous 
layer, lymph node metastasis, distant metastasis and 栿+桇 
of TNM stage were 86.1%, 66.7%, 90%, 76.1%, 80.6%, 83.3% 
and 95%, respectively (Table 1).         
 
Figure 1. EGFR expression in normal gastric tissue and gastric 
cancer tissue. 
A: Normal gastric tissue staining (SP伊200); B: EGRF positive staining 
in gastric cancer tissue (SP伊200).   
3.2. Analysis of relationship between EGFR expression and 
survival rate of gastric cancer patients, tumor size
  The one-year survival rate of patients with positive EGFR 
expression was 80% (36/45), while that of those with negative 
EGFR expression was 96.97% (32/33), with significant 
difference (P<0.05). The three-year survival rate of those 
with positive EGFR expression was 35.56% (16/45), while that 
of those with negative EGFR expression was 81.82% (27/33), 
with significant difference (P<0.05). The five-year survival 
rate of those with positive EGFR expression was 6.67% (3/45), 
while that of those with negative EGFR expression was 
36.36% (12/33), with significant difference (P<0.05) (Table 
2). The EGFR expression level was evaluated by the mean 
optical density value after immunohistochemical staining. 
The analysis of the correlation between EGFR expression 
level and life span was conducted, and they found to be 
negatively correlated. Using EGFR expression level as 
the independent variable and patients’ life span as the 
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dependent variable, the acquired regression equation was: 
y=79.034 1-52.416 5x (Figure 2). The relationship between 
EGFR expression level and tumor size was analyzed, and 
the linear correlation between them was obtained by least 
square fitting method (Figure 3). 
Table 1
Relationship between EGFR expression and clinicopathological 
parameters of gastric cancer.
Factor Cases (n)
EGFR
Positive P value
Total number of positive 40(57.7%)
Gender
Male 40 25(62.5%) 氈
2=0.778
Female 38 20(52.6%)    P=0.378
Age
＜50 25 18(72%) 氈
2=3.086
≥50 53 27(50.9%)    P=0.079
Tumor size
＜5 cm 42 14(33.3%) 氈
2=22.122
≥5 cm 36 31(86.1%)    P=0.000
Tumor position
Superior part 22   5(22.7%) 氈
2=11.369
Middle part 18 12(66.7%)    P=0.003
Inferior part 38 28(73.7%)
Differentiation
Well-differentiated 26   5(19.2%) 氈
2=19.562
Moderately differentiated 22 13(59.1%)    P=0.000
Poorly differentiated 30 27(90%)
Depth of invasion
Not into serous layer 32 10(31.3%) 氈
2=15.543
Into serous layer 46 35(76.1%)    P=0.000
Lymph node metastasis
No 42 16(38.1%) 氈
2=14.318
Yes 36 29(80.6%)    P=0.000
Distant metastasis
No 60 30(50%) 氈
2=6.303
Yes 18 15(83.3%)    P=0.012
TNM stage
栺+栻 58 26(44.8%) 氈
2=15.338
栿+桇 20 19(95%)    P=0.000
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Figure 2. Relationship between EGFR expression level and life span 
of patients. 
Table 2
Relationship between EGFR expression and the life span of gastric. 
cancer patients Negative Positive
Total cases 33 45
1-year survival 32 36
3- year survival 27 16
5- year survival 12 3
Median survival time(month) 49 28
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y=5.970 3x-0.536 0, err=32.917 1
y=2.613 2x2+11.3455x-3.044 9, err=27.946 6
 
Figure 3. Relationship between EGFR expression level and tumor 
size
3.3. Analysis of the survival curve of gastric cancer patients 
  The 5-year life span data of 78 gastric cancer patients 
were collected. Kaplan-Meier method was adopted for 
single factor survival analysis. The survival curve of gastric 
cancer patients was drawn, and the log-rank test was 
conducted (Figure 4). It was clear shown in Figure 3 that the 
survival rate of gastric cancer patients with negative EGFR 
expression was higher than that of gastric cancer patients 
with positive EGFR expression.    
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Figure 4. Kaplan-Meier analysis of the life span of gastric cancer 
patients. 
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4. Discussion
  Worldwide, gastric cancer is the fourth most commonly 
diagnosed cancer and the second most common cause of 
cancer death[11], accounting for almost 10% of all cancer 
deaths in 2008[12]. EGFR expresses in 43% of the gastric 
cancer patients and highly expresses in 11% of them[13]. 
EGFR signal abnormity plays an important role in the 
development of many human tumors. EGFR combines 
with its ligand to form homo- or hetero- dimers in the cell 
surface, and thus activates three main signal pathways in 
the downstream: Ras/Raf/MAPK pathway, Phosphatidyl 
inositol triphosphate (P13K) and AKT pathway, JAK and 
STAT pathway[14]. These signal transduction pathways 
finally mediate a series of processes including cell 
differentiation, survival, migration, invasion, adhesion and 
cell damage repair. The EGFR targeting therapy can block 
the activation of signal transduction pathway, thus achieving 
the goals of treatment[15]. It has been found that the 
EGFR overexpression participates in the oncogenesis and 
proliferation of tumor cells. EGFR involves in the tumor cell 
metabasis through various mechanisms like reconstruction, 
adherence, transference and expression of cytoskeleton, 
and activation of protein lipase[16]. EGFR overexpression is 
also associated with the poor prognosis of resectable gastric 
cancer[17]. We found that the EGFR positive expression 
rate in gastric cancer tissue was 57.7%, and the expression 
of EGFR was also closely related to tumor size, position, 
differentiation, invasive depth, whether having lymph node 
metabasis and distant metabasis, and TNM stage. All these 
indicated that EGFR took part in the biological behaviours 
like proliferation, invasion and metabasis of gastric cancer 
tumor cells. At the same time, the survival rate of patients 
with positive EGFR expression was obviously lower than that 
of patients with negative EGFR expression. EGFR expression 
level had quantitative relationship with the patients’ life 
span and tumor size. All these results indicated that EGFR 
may influence the process of tumor and finally influence the 
prognosis of patients.           
  There are various reports about EGFR expression in gatric 
cancer, and about 9%-62.7% of the reported expression 
differences may be caused by different sample sizes, 
detection methods or standards for evaluation. Some 
reported that EGFR did not express in normal gastric 
mucosa but highly expressed in gastric cancer tissues, and 
the EGFR expression may be related to the amplification 
and mutation of EGFR gene, the continuous activation of 
EGFR and the activation of abnormal signal transduction 
pathway. However, it is controversial about whether the 
high EGFR expression in gastric cancer is caused by gene 
amplification or gene mutation. Kimura et al[18] found high 
EGFR expression but did not found gene amplification. 
However, Mitsui et al[19] found high EGFR expression and 
4% gene amplification rate. Some reported the EGFR gene 
mutation in the kinase area. Moutinho et al[20]  found the 
EGFR gene mutaion in 6 of the 77 gastric cancer patients. 
Kimura et al[21]  found mutation in one of the six gastric 
cancer cell lines in the in vitro mutation research. The 
mechanism of high EGFR expression in gastric cancer is not 
clear because the amplification and mutation rates of EGFR 
gene are low. The results of our experiment indicated that 
EGFR did not express in normal tissue, which was consistent 
with the previous reports. EGFR specific expression exists 
in gastric cancer, the survival rate and life span of patients 
with positive EGFR expression are obviously lower than 
those with negative EGFR expression, and therefore, EGFR 
can be the ideal target for gastric cancer treatment. With 
the in-depth studies, people can design the more effective 
EGFR monoclonal antibody against gastric cancer. 
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